The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 0.96 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as Theravance Biopharma, Inc. reports it. History and quarterly detail are in the app.
- Yupelri Monotherapy$93.3M
- Collaborative Arrangement Revenue$75.0M
- Licensing And Milestone$32.5M
- Milestone$25.0M
- License$7.5M
Latest filings
- 8-K · Company announcement2026-08-25
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-06-29
- 8-K · Company announcement2026-06-23
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Theravance Biopharma, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Theravance Biopharma, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.